PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab
Journal article published in 2016 by
S. Loibl,
I. Majewski 
,
V. Guarneri,
V. Nekljudova,
E. Holmes,
E. Bria,
C. Denkert,
C. Schem,
C. Sotiriou,
S. Loi,
M. Untch,
P. Conte ,
R. Bernards,
M. Piccart,
G. von Minckwitz
and other authors.
,
V. Guarneri,
V. Nekljudova,
E. Holmes,
E. Bria,
C. Denkert,
C. Schem,
C. Sotiriou,
S. Loi,
M. Untch,
P. Conte ,
R. Bernards,
M. Piccart,
G. von Minckwitz
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Published version:
archiving forbidden
Data provided by 
Abstract
The predictive value of PIK3CA mutations in HER2 positive (HER2+) breast cancer treated with neoadjuvant anti-HER2 and chemotherapy has been reported, but the power for subgroup analyses was lacking.